The Consensus Conference on Brain Tumor Definition was facilitated by the Central Brain Tumor Registry of the United States and held on November 10, 2000, in Chicago, Illinois, to reach multidisciplinary agreement on a standard definition of brain tumors for collecting and comparing data in the U.S. The Brain Tumor Working Group, convened in 1998 to determine the status of brain tumor collection in the U.S., outlined 4 recommendations of which the first 2 guided the discussion for the Consensus Conference: (1) standardization of a definition of primary brain tumors that is based on site alone, rather than on site and behavior, and that can be used by surveillance organizations in collecting these tumors; and (2) development of a reporting scheme that can be used for comparing estimates of primary brain tumors across registries. Consensus was reached on the collection of all primary brain tumor histologies found and reported in the brain or CNS ICD-O site codes (C70.0-C72.9 and C75.1-C75.3), including those coded benign and uncertain as well as those coded malignant. In addition, a comprehensive listing of histologies occurring in the brain and CNS, based on the CBTRUS grouping scheme, was formulated to provide a template for reporting in accordance with the second recommendation of the Brain Tumor Working Group. With consensus achieved on the first 2 recommendations, the stage is set to move forward in estimating additional resources necessary for the collection of these tumors, including funding, training for cancer registrars, identifying quality control measures, and developing computerized edit checks, as outlined in the last 2 recommendations of the Brain Tumor Working Group.
After lagging behind other brain tumor disciplines in the 1980s, the epidemiology of brain tumors is now making progress on several fronts. The Central Brain Tumor Registry in the USA has made a complete description of primary brain tumors available to researchers. International data suggest that environmental components in the etiology of brain tumors are likely to be widely dispersed by geography and demographic subgroups. There are few proven causes of brain tumors: high-dose ionizing radiation, inherited genetic syndromes and AIDs-related brain lymphomas. Promising avenues of research include the role of immune function, genetic components in families, metabolic and DNA-repair pathways and neurocarcinogen exposures.
Recent trends in corpus uterine cancer incidence rates were explored using 1979-86 data from the Surveillance and End Results Program (SEER); recent trends in hospitalizations for corpus uterine cancer were explored using 1979-86 data from National Hospital Discharge Surveys (NHDS); and recent trends in exogenous hormone use were delineated using data from the 1980, 1981, and 1985 National Ambulatory Medical Care Surveys (NAMCS). Uterine cancer incidence rates using SEER data have continued to decline since 1979. An acceleration in the decline since 1983-84 is suggested in all women and in women with intact uteri ages 45-64. IntroductionIncidence rates of cancer of the corpus uterus showed striking increases in the early 1970s following increases in use of postmenopausal estrogens. 1-3 Subsequently, incidence rates of corpus uterine cancer declined in the late 1970s following declines in use of estrogens. ' Since 1980, there has been an increase in use of progestins cycled with estrogens in an effort to combat the carcinogenic effect of unopposed estrogens while allowing for a protective effect of estrogens on osteoporosis.4 The effect of exogenous progesterones on trends in uterine cancer, however, has not been documented. The purpose of the current paper is to delineate more recent time trends in corpus uterine cancer incidence and hospitalization rates in the 1980s in relation to the increasing use of exogenous progestins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.